Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same author

Radiotherapy dose escalation in glioblastoma: the thin ice of of historical controls.

The Lancet. Oncology·2026

Same author

Surgical resection or bevacizumab for treatment of radiation necrosis-associated cerebral edema in patients with brain metastases: A single center experience.

Neuro-oncology advances·2026

Same author

cIMPACT-NOW update 12: Refining Pathology-based Risk Stratification and Grading for IDH-mutant Gliomas.

Neuro-oncology·2026

Same author

Gods do play dice: The activity of regorafenib in glioblastoma not confirmed.

Neuro-oncology·2026

Same author

Delta-like ligand 3 expression in isocitrate dehydrogenase-mutant and isocitrate dehydrogenase-wildtype glioma is largely retained at recurrence, supporting its potential as a therapeutic target.

Neuro-oncology advances·2026

Search research articles

Related Experiment Video

Updated: Apr 26, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Interview: Improving outcome for brain tumor patients

Martin J van den Bent¹

¹Neuro-oncology Unit, ErasmusMC - Daniel den Hoed Cancer Center, Groene Hilledijk 301, Rotterdam, The Netherlands. m.vandenbent@erasmusmc.nl.

|July 24, 2014

Summary

No abstract available in PubMed .

More Related Videos

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

Implementation of Minimally Invasive Brain Tumor Resection in Rodents for High Viability Tissue Collection

Implementation of Minimally Invasive Brain Tumor Resection in Rodents for High Viability Tissue Collection

Published on: May 9, 2022

Related Experiment Videos

Last Updated: Apr 26, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

Implementation of Minimally Invasive Brain Tumor Resection in Rodents for High Viability Tissue Collection

Implementation of Minimally Invasive Brain Tumor Resection in Rodents for High Viability Tissue Collection

Published on: May 9, 2022